hrp0084p1-142 | Turner & Puberty | ESPE2015

Fracture Incidence is Not Associated with the Six-Year Development of Trabecular BMD in Paediatric Turner Syndrome Patients

Soucek Ondrej , Sumnik Zdenek , Snajderova Marta , Kolouskova Stanislava , Lebl Jan

Background: Increased fracture risk and decreased bone mineral density (BMD) have been demonstrated by several studies in Turner syndrome (TS). However, longitudinal data on BMD development in childhood and adolescence and a reliable densitometric predictor of fractures in TS are still lacking.Objective and hypotheses: Our aim was to longitudinally assess BMD in paediatric TS patients and test whether trabecular BMD development over six years of observat...

hrp0084p3-940 | GH & IGF | ESPE2015

GH Dosing Patterns in Children with Isolated GH Deficiency and Multiple Pituitary Hormone Deficiency Enrolled in the NordiNet® International Outcome Study

Snajderova Marta , Pournara Effie , Pedersen Birgitte Tonnes , Blankenstein Oliver

Background: Long-term monitoring of GH treatment in children is very important.Objective and hypotheses: To describe patterns of GH dosing in clinical practice in children with isolated GH deficiency (IGHD) and multiple pituitary hormone deficiency (MPHD).Method: We analysed 7 years of GH treatment data from NordiNet® International Outcome Study (IOS) (NCT00960128), an observational study evaluating the long-term effectiveness...

hrp0094yb1.5 | Year of Paediatric Endocrinology 1 | ESPE2021

Bone, Growth Plate and Mineral Metabolism

Baroncelli Marta , Raimann Adalbert , Padidela Raja , Nilsson Ola ,

The skeletal research field develops rapidly and has produced several exciting findings in the last year and includes advances in the treatment of rare skeletal disorders and an ever deeper understanding into the fundamental molecular mechanisms that control skeletal development, metabolism, growth, and mineralization. The targeting of the C-type natriuretic peptide (CNP) pathway and options to directly antagonize the overactivity of the FGFR3 pathway in achondroplasia continu...

hrp0097fc4.4 | Growth and syndromes (to include Turner syndrome) | ESPE2023

Growth failure in aggrecan haploinsufficiency is due to a decrease in growth plate matrix volume and hypertrophic cell size

Bendre Ameya , Ottosson Lars , Baroncelli Marta , Dou Zelong , Nilsson Ola

Background: Heterozygous loss-of-function mutations in the aggrecan gene (ACAN) cause autosomal dominant short stature with advanced bone age, early-onset osteoarthritis and intervertebral disc disease (SSOAOD; OMIM#165800). ACAN mutations is a relatively common finding in idiopathic short stature (ISS) and has been reported to be the cause of growth failure in approximately 2% of children with ISS. However, the underlying cellular and molecular mechanisms by ...

hrp0097p1-108 | GH and IGFs | ESPE2023

A challenging case of Pituitary Gigantism

Chandwani Manju , Subbarayan Anbezhil , Levy Miles , Korbontis Marta

A 4.9-year-old girl presented with a 6-month history of excessive body odour and suspected breast development. Family history was significant for presence of Lynch syndrome in both her father and paternal grandmother. At presentation, she was pre-pubertal but tall for her age. Her height was 124 cm (SDS 3.5), and weight was 27.1 kg (SDS 2.69). Her height velocity was accelerated at 15 cm/year and bone age was advanced at 7 years. Investigations revealed an elevated IGF-1 (500 ...

hrp0097p1-167 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2023

Low-dose pioglitazone for polycystic ovary syndrome in adolescent girls:differential fat-mass redistribution by HOTAIR rs1443512 genotype

de Zegher Francis , Diaz Marta , Ibañez Lourdes

Introduction: Adolescent polycystic ovary syndrome (PCOS) is characterized by androgen excess and oligo-amenorrhea, and often results from ectopic lipid storage due to a mismatch between early adipogenesis and later lipogenesis. Endogenous HOTAIR and exogenous pioglitazone are enhancers of subcutaneous adipogenesis, particularly in the gluteofemoral region. The A allele of HOTAIR rs1443512 is an equivalent of a natural knock-down and is thus a candidate to inf...

hrp0097p2-248 | Late Breaking | ESPE2023

Pediatric Hyperthyroidism in the Time of COVID-19: An Updated Presentation Analysis

Sol Ventura Paula , Gonzalez Alba , Valls Aina , Murillo Marta

Abstract: The SARS-CoV-2 virus uses ACE2 combined with the transmembrane-protease TMPRSS2 to enter and infect thyroid follicular cells. Studies have reported a higher incidence of hyperthyroidism cases during the COVID-19 pandemic compared to pre-pandemic periods. Studies have also been reported cases of thyroid dysfunction early after mass covid vaccinations. However, there are insufficient data to confirm these associations in children.<p class="abstext"...

hrp0095p2-11 | Adrenals and HPA Axis | ESPE2022

Differences in The Management of Classic Childhood Congenital Adrenal Hyperplasia in Spain According to A Patients Association

Murillo-Vallés , Valls-Llussà Aina , Martinez-Couselo Silvia , Salinas-Vert Isabel , de Diego-Suarez Marta Marta

Objective: Despite published guidelines, there is no single approach to management in congenital adrenal hyperplasia (CAH). The objective of the study was to explore the variations in treatment for CAH in Spain.Material and methods: A retrospective study in a single center was done analyzing the data provided by patients and relatives through the Spanish Association of CAH from a online survey of 25 questions. It was dif...

hrp0089p2-p080 | Diabetes &amp; Insulin P2 | ESPE2018

Betatrophin as a New Biomarker of Type 1 Diabetes Mellitus in Paediatrics

Ara Laura Bosch i , Villalba Adria , Murillo Marta , Fonolleda Mireia , Vazquez Federico , Rodriguez-Fernandez Silvia , Vives-Pi Marta , Bel Joan

Introduction: Type 1 Diabetes Mellitus (DM1) is an autoimmune disease resulting from the destruction of pancreatic β cells. After the diagnosis, up to 80% of patients spontaneously experience partial remission (PR) for months. New biomarkers are being studied, such as the betatrophin protein (ANGPTL8) of unknown function, but which could be involved in the evolution of DM1, in this phase of RP and even used as a therapeutic target.Methods: Observati...

hrp0097p1-584 | Thyroid | ESPE2023

National multi-center study of reevaluation of thyroid function in premature infants of less than 32 weeks of gestation and/or less than 1500g admitted to neonatal units

Campos-Martorell Ariadna , Ares Segura Susana , J Chueca Gandulain Maria , Grau Bolado Gema , Navarro Constanza , Serrano Costa Loreto , Gale Pola Ines , Fernandez Vallespin Laura , Pellicer Casanova Laura , Montaner Ramon Alicia , Puig Amoros Elisabet , Mora Sitja Marina , Rodriguez Amparo , Casano-Sancho Paula

Preterm and low birth weight(LBW) newborns are at risk of thyroid dysfunction during a critical period for neurodevelpment and this dysfunction can be missed in congenital hypothyroidism screening program(CHSP). Consequently, reassessment of thyroid function has been promoted in neonatal units, added to CHSP.Objectives: To evaluate prevalence and risk factors of thyroid dysfunction in≤32weeksGA and/or 1500g newborn, and compare differ...